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Abstract
Introduction: The thrombocytopenia of the Paris-Trousseau (TCPT) type is a contiguous gene syndrome
characterized by mild bleeding tendency, variable thrombocytopenia (THC), abnormal giant alpha-granules
in platelets and dysmegakaryopoiesis: it derives from a constitutional deletion of chromosome 11 leading
to the loss of FLI1, a transcription factor involved in megakaryocyte differentiation and maturation. Case
report: A women with an acquired, isolated THC developing over 10 yr showed morphological features
typical of TCPT in platelets and bone marrow (BM). Twenty years after the onset of THC, the other
hematological parameters are still normal and the patient is well. Results: Clonal hemopoiesis was shown
and chromosome analyses performed on BM revealed a clone with 45 chromosomes and a complex
unbalanced translocation involving chromosomes 2, 3, and 11. The anomaly was present in the majority of
bone marrow cells but only in a few peripheral blood elements. A microarray-based comparative genomic
hybridization defined the deleted region of chromosome 11 including the FLI1 locus that was missing.
Conclusion: Although our patient presented with nearly all the characteristics of TCPT, her illness was
acquired instead of being inherited and the most appropriate diagnosis is that of the unilineage dysplasia
‘refractory THC.’ This observation suggests that appropriate cytogenetic investigations should be always
considered in patients with acquired THC of unknown origin.
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FLI1 is a member of the ETS family of transcription
factors. It trans-activates several genes involved in megak-
aryocyte (Mk) differentiation and maturation, as ITGA2
(1), GP9 (2), GPIBA (3), and c-mpl (4), and its targeted
disruption in mice results in a dramatic reduction in MKs
number and size (5,6). Subtle constitutional deletions of
the long arms of chromosome 11, including the FLI1lo-
cus, causes the Paris-Trousseau syndrome (TCPT, OMIM
# 188025) (7), a thrombocytopenia with abnormal giant
alpha-granules in platelets, whereas larger deletion imply
a variety of additional phenotype changes, often recog-
nized as Jacobsen syndrome (OMIM # 147791) (8). Thus,
defective FLI1 is one of the many causes of inherited
thrombocytopenia that is considered in the differential
diagnosis of these disorders.
We report here the ﬁrst patient with an acquired form of
thrombocytopenia associated with a clonal chromosome
anomaly in the bone marrow (BM) with the loss of FLI1
that leads to the picture of TCPT.
Patient and methods
Case report
An Italian young woman, born in 1972 from non-consan-
guineous parents and with irrelevant family history, was
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referred for thrombocytopenia. She had undergone a left
nephrectomy for congenital hydronephrosis at the age of
11 yr. Since then she made regular blood tests that showed
a progressive reduction in platelet count (Fig. 1), while the
other blood cells were always within normal limits. At the
age of 23 yr, her platelet count fell steadily below
100 9 109/L, and she was diagnosed with autoimmune
thrombocytopenia. At 32, her platelet count was lower than
50 9 109/L and she received prednisone 1 mg/Kg/d for
3 months without any beneﬁt. Soon after, BM examination
revealed an increased number of megakaryocytes (Mks),
often small. At 36, administration of intravenous immuno-
globulins (0.4 g/kg/d for 5 d) did not increase platelet count.
Examined for the ﬁrst time at our institution in 2009, at
the age of 37, she had no bleeding tendency. Blood count
showed: Hb 15.6 g/dL, MCV 82.9 fL, WBC 5.5 9 109/L
(64.5% neutrophils, 24% lymphocytes, 4% monocytes, 7%
eosinophils, and 0.5% basophils), platelets 42 9 109/L,
MPV 15.8 fL. In vitro platelet aggregation, measured by the
densitometric method of Born after stimulation with collagen
4 lg/mL, ADP 5 lM and ristocetin 1.5 mg/mL was within
the normal range (data not shown).
Evaluation of May–Grünwald–Giemsa (MGG) stained
peripheral blood (PB) ﬁlms did not identify red cell or leu-
kocyte abnormalities, but it showed platelet macrocytosis
with some elements larger than red cells (giant platelets).
Moreover, a few platelets (0.3%) had only one, large, azuro-
philic granule (Fig. 2). Immunoﬂuorescence microscopy (9)
revealed that these giant granules contained thrombospondin
1 (TSP1) and platelet factor 4, thus indicating that they
were abnormally large alpha-granules (Fig. 2). To better
deﬁne their morphologic features, we performed electron
microscopy (EM) study of peripheral blood platelets, but
we failed to identify abnormally large granules, proba-
bly because of their extreme rarity and the difﬁculty of
examining a sufﬁcient number of cells by this technique.
MGG-stained BM touch preparations displayed normocel-
lular marrow with markedly increased, often clustered, Mks.
The numerous Mks were dysplastic with prevalence of
mononuclear micromegakaryocytes, small binucleate Mks,
and Mks with agranular or vacuolated cytoplasm (Fig. 2).
Erythroid and granuloblastic lineages were morphologi-
cally normal with 3% blasts and slightly increased eosinoph-
ils. PERLS’s staining demonstrated the absence of ring
sideroblasts among erythroid precursors (not shown).
Serum thrombopoietin (TPO) level, evaluated as previ-
ously reported (10), was within the normal range (29.7 pg/
mL, n.v. 6.9–54.4). Evaluation of clonality with the method
of HUMARA in peripheral blood neutrophils revealed clonal
hemopoiesis (11).
At the last evaluation (June 20, 2012), the patient’s
clinical condition was unchanged and the only alteration of
blood count was still a moderate thrombocytopenia
(51 9 109 platelets/L).
The Ethic Committee of the IRCCS San Matteo Hospital
Foundation approved this study and the investigated patient
gave written informed consent.
Cytogenetic methods
Chromosome analyses were performed with routine methods
and QFQ-banding technique on BM direct preparations and
24–48 h cultures, on PB unstimulated and phytohaemagglu-
tinin (PHA)-stimulated cultures. Fluorescence in situ hybrid-
ization (FISH) was used to better deﬁne the complex
structural anomaly found in the BM with multipainting
technique with the 24XCyte-MetaSystems’ 24 color kit
(Metasystems GmbH, Althussheim, Germany); the BAC
probe RP11-744N12, which recognizes a sequence in band
q24.3 of chromosome 11, including the gene FLI1, was used
for FISH on BM mitoses and interphase nuclei, and BAC
probes RP11-1152N24 (2q36.1) and CTC-774G23 (3p12.3)
were used in double color FISH (Invitrogen Corporation,
Carlsbad, CA, USA).
Microarray-based comparative genomic hybridization
(a-CGH) with the 244K genome-wide system (Agilent
Technologies Inc., Santa Clara, CA, USA) was performed
according to the manufacturer’s instruction on DNA from
BM. The DNA was extracted using the Qiagen Blood and
Tissue Kit (QIAGEN GmbH, Hilden, Germany), and com-
petitor DNA was purchased from Promega (Madison, WI,
USA). Slides were scanned using Agilent’s microarray scan-
ner G2565CA and microarray images were analyzed using
Agilent’s Feature Extraction 10.7.3.1 software, and by
Agilent’s Genomic Workbench software (5.0.14). All map
positions in the results refer to the genome assembly hg18.
Results
Chromosome analyses performed on BM in November 2008
and October 2009 revealed a clone with 45 chromosomes
and a complex structural anomaly involving chromosomes 2,













Figure 1 Time course of platelet count. A progressive reduction in
platelet count began when the patient was 12-yr old and led to a
severe thrombocytopenia with <50 9 109/L platelets in about 15 yr.
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translocation, leading to partial monosomy of the long arms
of chromosome 2, of the pericentromeric region (short and
long arms) of chromosome 3, and of the long arms of chro-
mosome 11. The anomaly was present in the majority of the
cells, together with normal cells, with identical proportions at
the two times of analysis: 45,XX,der(2)t(2;3)(q36.1;p12.3),-
3,der(11)t(3;11)(q11.2;q14.3)[39]/46,XX[1]. The same abnor-
mal clone was detected in one single cell from PB unstimu-
lated culture in October 2009, and in PHA-stimulated
cultures (2/40 mitoses in June 2009, and 2/31 in October
2009).
The multipainting technique and the FISH results with
the BAC probes conﬁrmed the results of the chromosome
analyses, and a-CGH on BM (October 2009) precisely
deﬁned the regions of imbalance, which may be described
by the following formulation: arr2q36.1qter (221 960 583–
242 689 978)91, 3p12.3p11(74 438 852–90 391 698)91,
11q14.3qter(91 175 044–134 432 265) 9 1, (Fig. 3). On
chromosome 3, a-CGH revealed the short arms monosomy,
whereas no imbalance of the long arms was put in evidence,
because the breakpoint was close to the centromere, and
the oligonucleotides spotted on the a-CGH platform did
not cover this region. In particular, the deleted region of
chromosome 11 included the FLI1 locus that was therefore
missing: FISH with the probe RP11-744N12 conﬁrmed its
loss on mitoses and on BM interphase nuclei (200 nuclei
out of 313 in October 2009).
Discussion
TCPT is a rare contiguous gene syndrome because of a con-
stitutional interstitial deletion or microdeletion of the long
arms of chromosome 11, with the loss of one allele of the
gene FLI1 (7), in some cases with apparent autosomal domi-
nant inheritance. As in many inherited thrombocytopenias,
blood platelets are typically larger than normal, but a distin-
guishing feature of TCPT is that a little percentage of circu-
lating platelets has one or more giant granules that derive
from the fusion of alpha-granules. Another characteristic
ﬁnding of TCPT is the abundance of BMMks, which appear
severely dysplastic, with many small and immature forms.
Our patient presented with nearly all the hematological
characteristics of TCPT. She had both macrothrombocytope-
nia and some platelets with giant alpha-granules, a greatly
increased number of BM Mks, with most of them show-




Figure 2 (A-F) BM touch preparation. BM smears showed normal erythroid and granulocytic cells (A) and evident dysmegakaryopoiesis. (B) An
immature Mk with vacuolated cytoplasm. (C) A Mk with hypogranular cytoplasm (top right); the other Mk looks normal (bottom left). (D) A large
Mk with a single large round nucleus and hypogranular vacuolated cytoplasm. (E) A small binucleate Mk. (F) A micromegakaryocyte with scanty
granular cytoplasm. (G-I) Peripheral blood film, black and white. Rare platelets with a single large granule are observed in MGG-stained film (G
and H). Immune-staining for TSP1 of peripheral blood films (I): the platelet on the left has normal alpha-granule content and distribution, while that
on the right have one prominent, large granule. Scale bars correspond to 10 micronmeters.
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chromosome structural anomaly including the loss of one
FLI1 allele. As this chromosome defect affected most of the
BM cells but only a very limited proportion of peripheral
blood elements, we can conclude that it was acquired in
BM, instead of being constitutional as in the TCPT patients
reported so far: consequently, the disease was not congenital,
but gradually developed over a period of more than 20 yr.
The positivity of the assay for clonal hematopoiesis agrees
with cytogenetic data. An alternative, more convincing diag-
nosis for our patients is ‘refractory thrombocytopenia’, a
form of myelodysplastic syndrome (MDS) that, together
with ‘refractory anemia’ and ‘refractory neutropenia,’ consti-
tutes the category of ‘refractory cytopenias with unilineage
dysplasia’, as deﬁned in the 2008 revision of the World
Health Organization classiﬁcation of myeloid neoplasms and
acute leukemias (12). Our patient meets all the criteria for
refractory thrombocytopenia: she acquired an isolated throm-
bocytopenia with <100 9 109 platelets/L and had no blasts
in peripheral blood; more than 10% of BMMks had clearly
dysplastic features; no erythroid precursors were ring sidero-
blasts and BM blasts were <5%. What is puzzling in this
MDS patient is the very prolonged clinical course of her ill-
ness: although platelet count fell below 150 9 109/L more
than 20 yr ago and below 100 9 109/L 17 yr ago, thrombo-
cytopenia continues to be the only cytopenia, because both
the value of Hb and the number of neutrophils are still within
the normal limits. Also taking into account that thrombocy-
topenia was identiﬁed at its ﬁrst appearance because the
patient was accustomed to carry out regular blood tests, an
event-free survival longer than 20 yr is surprising, because
much shorter clinical courses have been described for refrac-
tory thrombocytopenias reported so far (13, 14). According
to the International Scoring System for Evaluating Prognosis
in Myelodysplastic Syndromes (15), our patient would have
an intermediate-1 risk and an age-related expected survival
of 5.2 yr. Also, in this respect, the evolution of the disease
was therefore much slower than expected.
The trend of platelet count described in Fig. 1 seems to
indicate that, after a 15-yr-long gradual descent, the number
of platelets has remained fairly stable over the last 10 yr.
We may speculate that platelet count decreased while the
abnormal BM clone with defective FLI1 was expanding, and
that the degree of thrombocytopenia remained subsequently
stable because no other genetic defects hampering megak-
aryopoiesis occurred. Based on these considerations, we
believe that the diagnosis of a refractory thrombocytopenia
that mimics TCPT because of the loss of one FLI1 allele is
appropriate for this patient. Our observation emphasizes that
every patient with MDS is a story unto itself and that the
prognostic indicators should be used with caution in mak-
ing treatment decisions. In particular, the complex genetic
defect of our patient was compatible with a very long sur-
vival without any severe clinical defects despite the poor
prognosis indicated by the IPSS prognostic index.
In conclusion, the patient we described here acquired a
MDS that has posed problems of differentiation not only
from immune thrombocytopenia but also from the TCPT.
We believe, therefore, that this rare form of MDS should be
considered in the differential diagnosis of all patients
with acquired thrombocytopenias and occasional giant plate-
let alpha-granules. Being a clonal chromosome aomaly the
primary event leading to thrombocytopenia in the patient
reported here, we suggest that cytogenetic investigations,
including a-CGH, should always be considered in the
Figure 3 a-CGH profiles of chromosomes 2, 3, and 11 showing the unbalanced regions.
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diagnostic evaluation of patients with acquired thrombocyto-
penia of unknown origin with the clinical picture of our
patient.
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